Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) reported no material operational impact from the Iran and Middle East conflict and said record revenue momentum continues. Q3 2025 revenue reached $17.1M (+38% YoY); gross profit $2.6M (+116%) with a 15.21% margin; cash rose to $4.63M from $0.66M.
The company said U.S. rollout of NOOR collagen is on track, produced in GMP/FDA-registered facilities, and projected to exceed $12M revenue within 12 months with ~75% gross margins.
Positive
- Revenue $17.1M in Q3 2025, up 38% YoY
- Gross profit $2.6M, a 116% increase with 15.21% margin
- Cash position $4.63M, up from $0.66M at Q2 2025
- NOOR U.S. projected >$12M revenue within 12 months at ~75% gross margin
- Products manufactured in U.S. GMP/FDA-registered facilities, reducing tariff and logistics risk
Negative
- None.
News Market Reaction – COSM
In the Apr 10 session, COSM gained 3.45%, reflecting a moderate positive market reaction. Argus tracked a peak move of +8.9% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Crypto Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | U.S. product launch | Positive | +0.6% | Announced Q2 2026 U.S. launch of Liv18 liver health supplement. |
| Apr 01 | Clinical validation | Positive | +0.6% | C-Scrub Wash 4% met EN 12791 standard, supporting hospital market expansion. |
| Mar 19 | Growth and guidance | Positive | -0.4% | Update on record growth, U.S. expansion, >$12M NOOR projection and LOI acquisition. |
| Mar 11 | Crypto treasury move | Positive | +1.1% | Purchased $600,000 of Bitcoin, lifting digital asset holdings to $3.1M. |
| Feb 19 | Asset valuation update | Positive | -5.9% | Highlighted ~$15M real estate value exceeding market cap and exploring monetization. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent crypto-tag news has often been positive operationally but produced mixed price reactions, with both gains and notable pullbacks.
Over the last few months, COSM has issued multiple crypto-tagged updates, from U.S. product launches and clinical validation to treasury crypto purchases and asset-valuation highlights. Price reactions have been modest, with several positive announcements (Liv18 launch, C‑Scrub EN 12791 success, Bitcoin purchases) seeing small gains, while valuation and growth updates around real estate and U.S. expansion sometimes coincided with declines. Today’s update on record revenue and NOOR expansion fits this stream of growth-focused communications.
Key Terms
gmp-certified regulatory
fda-registered regulatory
adjusted ebidta financial
cagr financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, IL / ACCESS Newswire / April 10, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today confirmed that the ongoing conflict in Iran and broader Middle East geopolitical tensions have not had a material impact on the Company's operations, supply chain, or business performance. The Company also noted continued record revenue momentum and reaffirmed that its U.S. expansion, including the rollout of NOOR collagen, remains on track.
Geopolitical Resilience Underpins Global Platform
Cosmos Health operates through a diversified international platform spanning Europe, North America, and other key regions. The conflict in the Middle East and recent geopolitical developments have had a negligible impact on the Company's operations. Management expects strong growth momentum to continue as the Company advances toward sustained profitability.
Record Revenue Momentum Continues
The Company's most recently reported quarter, Q3 2025, marked a new all-time high, with revenue reaching
This record-setting momentum has continued into subsequent periods. More detailed financial information will be provided in conjunction with the Company's fourth quarter and full-year 2025 results, expected shortly.
NOOR U.S. Expansion Accelerating
Sales of Sky Premium Life NOOR collagen in the United States are already underway, with the product manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities, underscoring the Company's commitment to regulatory excellence and product integrity while mitigating tariff exposure and cross-border logistical risks.
The Company anticipates gross margins of approximately
Greg Siokas, CEO of Cosmos Health, stated: "Our business has never been stronger. Q3 2025 marked our highest revenue, gross profit, and gross margin in the Company's history - and that momentum has continued. Our geographically diversified platform insulates us from regional disruptions, while the accelerating U.S. expansion of Sky Premium Life NOOR represents a transformational growth opportunity. We expect NOOR U.S. revenues to exceed
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire